A multi-center phase II study of high dose interleukin-2 sequenced with vemurafenib in patients with BRAF-V600 mutation positive metastatic melanoma

by Joseph I. Clark, Jatinder Singh, Marc S. Ernstoff, Christopher D. Lao, Lawrence E. Flaherty, Theodore F. Logan, Brendan Curti, Sanjiv S. Agarwala, Bret Taback, Lee Cranmer, Jose Lutzky, Theresa L. Luna, Sandra Aung, David H. Lawson
Published 2018-07-01

Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysis

by F Stephen Hodi, Ahmad A Tarhini, John M Kirkwood, Zeynep Eroglu, Henry B Koon, Ni Kang, Vernon K Sondak, Harriet M Kluger, Sandra J Lee, Gary I Cohen, Laura F Hutchins, Donald P Lawrence, Kari L Kendra, David R Minor, Carrie B Lee, Mark R Albertini, Lawrence E Flaherty, Teresa M Petrella
Published 2021-05-01